BioCryst Pharmaceuticals | BCRX - Stock


BioCryst Pharmaceuticals reported $5.4M in Stock for its fiscal quarter ending in December of 2025.





Stock Change Date
Alnylam Pharmaceuticals USD 200.15M 117.43M Mar/2026
BioCryst Pharmaceuticals USD 5.4M 166K Dec/2025
Chugai Pharma JPY 276.85B 30.52B Dec/2025
Daiichi Sankyo JPY 608.55B 93.64B Sep/2025
Gilead Sciences USD 1.77B 11M Dec/2025
GlaxoSmithKline GBP 6.16B 233M Mar/2026
Glaxosmithkline GBP 6.12B 46M Sep/2025
Incyte USD 115.62M 14.56M Mar/2026
Ionis Pharmaceuticals USD 5.56M 4.49M Mar/2026
Karyopharm Therapeutics USD 4.04M 72K Dec/2025
Neurocrine Biosciences USD 64.5M 4.5M Mar/2026
Novavax USD 11.54M 1.97M Dec/2025
PTC Therapeutics USD 79.65M 26.96M Dec/2025
Regeneron Pharmaceuticals USD 3.1B 97.2M Mar/2026
Roche Holding CHF 7.6B 9M Jun/2025
Sarepta Therapeutics USD 914.74M 162.42M Dec/2025
Ultragenyx Pharmaceutical USD 52M 200K Dec/2025
Vertex Pharmaceuticals USD 1.77B 79.9M Mar/2026